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Table 1
TNC
MeanSD (range)
CD34+
MeanSD (range)
Total cells Pre-
thaw
190.852.2 (70-359),
x107
8.85.1 (1.3-28), x106
Post-
thaw
171.353.9 (49.1-414.8),
x107
6.73.6 (1.3-21.2), x106
Per kg BW Pre-
thaw
2.70.8 (1.1-5.7),
x107
1.20.7 (0.2-4), x105
Post-
thaw
2.40.8 (0.9-6.9),
x107
0.90.5 (0.3-3.6), x105
Viability
(%)
42.613.1 (19-71.4) 9110.9 (47.8-100)
Table 2
TNC CD34+
Washed Diluted Washed Diluted
Difference (%)
between pre- and post-
thaw cell numbers
MeanSD (range)
16.110.2
(0.7-43.8)
9.56.4
(0.2-26.8)
22.614.6
(0.8-57.9)
2615.5
(0.2-76)
Mann-Whitney
score
0.0001 0.0621
Spearman’s rho 0.8661 0.9487 0.8578 0.8079
Abstracts / Biol Blood Marrow Transplant 20 (2014) S257eS285S260Cell dose is a major criterion for cord blood unit (CBU) se-
lection for allogeneic stem cell transplantation (allo-SCT).
The aim of this study was the characterization of CBU cellular
composition after thaw, and comparisonwith corresponding
values at cryopreservation as reported by cord blood (CB)
banks.
The study included 87 CBUs, that were thawed for infusion
in the context of single (n¼3) or dual-unit (n¼42) allo-SCT
in adults with hematologic malignancies, from 8/2006 to
6/2013. Upon thawing, the cryoprotective solution (DMSO
10%) was either removed by centrifugation/washing
(38 CBUs) or diluted in a less hypertonic solution of Dextran
40/Human Albumin 2.5% (49 CBUs). Total nucleated cells
(TNC) were measured with a hematology analyzer, while
enumeration of CD34+ stem cells was performed by single-
platform ﬂow cytometry, according to ISHAGE guidelines. In
49 units, TNC and CD34+ cell viability was evaluated by
addition of 7-AAD dye and sequential Boolean gating
strategy.
TNC counts after thawing were lower compared to their
values at freezing (Wilcoxon test, p <10-4), and the dif-
ference was more pronounced in the units that were
washed prior to infusion (Tables 1 and 2). Total cell
viability was low (mean value, 42.6%), but this was mainly
due to neutrophils. Regarding CD34+ cells, there was a
signiﬁcant difference between absolute counts at cryo-
preservation and at thaw (p<10-4). Despite reduction post-
thaw, the counts of both TNC and CD34+ cells did correlate
with the corresponding values at cryopreservation by
Spearman’s analysis. Of note, washing seemed slightly
advantageous in terms of CD34+ recovery (Tables 1 and 2).
CD34+ cells retained high viability after thaw, with 90% of
CBUs (44 out of 49 tested) demonstrating CD34+ viability
80%. Viability of <50% was noticed in only one CBU that
failed to engraft.
In conclusion, CB cellular content and especially the CD34+
cell count is frequently shown to be inferior at thaw
compared to cryopreservation. This probably reﬂects both
the lack of standardization of CD34+ cell measurement and
the effect of thawing procedure. Therefore, CD34+ cell
viability may be a more meaningful marker for determining
CBU quality.GVH/GVL
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Introduction: The optimal management of patients with
steroid refractory acute GVHD (SR-GVHD) is not yet deﬁned.
We examined the clinical courses of patients with SR-GVHD
treated with Alemtuzumab.
Methods: SR-GVHD was deﬁned as progression with 3 days
of 2 mg/kg of steroids, incomplete response in 7 days or
inability to taper steroids by 14 days. Of 211 consecutive
hematopoietic cell transplantation (HCT) recipients between
April 2011 and May 2013, 34 (16%) recipients developed SR-
GVHD and received Alemtuzumab (30mg subcutaneously
every 14 days until progression or severe infectious com-
plications for a maximum of 5 doses. Overall responses (OR)
were evaluated by day 28 and 56 after administration of
Alemtuzumab (McMillan et al, 2002).
Results: Median time to onset of acute GVHD was 25 days
(range 7-127) post-HCT. All patients received systemic ste-
roids ﬁrst line and were deﬁned as SR-GVHD. Median time
from steroid initiation to Alemtuzumab therapy was 12 days
(range 5-46). A median of 3 doses was given (range 1-4).
Twenty seven patients (80%) were alive and evaluable for
response by day 28 with 48% OR in 13 patients (8 CR and 5
PR), while 14 (52%) did not respond by day 28. Twenty pa-
tients (60%) were alive and evaluable for response by day 56
among whom 45% OR was noted (8 CR and 1 PR). No addi-
tional responses were observed after day 28 if not responded
within the ﬁrst 2 doses.
Median overall survival (OS) was 125.5 days (range 74-
328). The group responding to Alemtuzumab by day 28
showed a longer duration of OS (median 156 days) compared
to the non-responders by day 28 (median 99 days; p¼0.03).
However, all but one patient died of infection (n¼10), GVHD
(n¼16), GVHD and infection (n¼6) or other (n¼1). Infectious
events were noted in all 34 patients, with 117 events
including bacterial (n¼65 in 33 patients), viral (n¼44 in 28
patients) and fungal infections (n¼8 in 8 patients). Even in
the patients responding to Alemtuzumab by day 28, there
was one long-term survivor who is still alive at 310 days at
last follow-up
Conclusion: Response to Alemtuzumab seems to be an in-
dicator for prolonged OS duration in patients with SR-GVHD
although an improvement of 57 days is of questionable
clinical signiﬁcance given the morbidity associated with this
therapy. However, Alemtuzumab therapy does not improve
OS primarily because of high rate of infectious complication.
Better supportive care is needed to improve outcome from
infections after Alemtuzumab therapy for SR-GVHD.
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